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 The recent article by Arber et al (1) detailing the 2016 revision of the 
World Health Organization (WHO) classification of myeloid malignancies and 
AML was timely and germane. Regarding myelodysplastic syndromes (MDS), the 
authors indicate diagnostic criteria, which include levels of dysplasia and 
cytopenias. They further indicated that ethnic variation should be taken into 
consideration in patients with borderline low neutrophil counts and that a 
diagnosis of MDS may still be made in 'rare cases with milder levels of cytopenia' 
when definitive morphologic and/or cytogenetic features are present (1, 2). The 
necessity of clarifying these criteria has major relevance, particularly with the 
advent of recently described group of indolent hematopoietic disorders which 
may represent precursor states of MDS such as idiopathic cytopenia of unknown 
significance (ICUS) (3-5), Idiopathic dysplasia of unknown significance (IDUS) 
(5,6), clonal hematopoiesis of unknown potential (CHIP) (7), and clonal cytopenia 
of unknown significance (CCUS) (4, 8, 9) that require distinction from MDS. It is 
recognized that ICUS is not necessarily myeloid (unrecognized 
lymphoid or plasma cell neoplasms may cause idiopathic 
cytopenias that may be classified initially as ICUS, and some 
patients with ICUS may eventuate into non-
hematopoietic/reactive disorders such as immune dysregulation), 
while IDUS is a morphological alteration with many potential 
causes that do not necessarily influence hematopoiesis in terms 
of the number of generated cells. These entities have been reviewed in 
the current NCCN MDS Practice Guidelines 1.2017 (10).  
 However, although the WHO perspective indicates that 'cytopenia is a sine 
qua non for any MDS diagnosis' (1), the recommended threshold levels of 
cytopenias they propose for this purpose are those previously reported in the 
International Prognostic Scoring System (IPSS) risk stratification categorization, 
that were used for prognostic but not diagnostic purposes [hemoglobin (Hb) 
10g/dL, absolute neutrophil count (ANC) 1.8x109/L, platelets 100x109/L] (11). As 
shown in Table 1, providing data from the International Working Group for 
Prognosis in MDS (IWG-PM) database that was used to generate the Revised-
IPSS (IPSS-R) (12), were these levels of cytopenias to be used to diagnose 
MDS, 18% of MDS patients and 23% of those with <5% marrow blasts, would 
lack any cytopenia and thus would not be classifiable as MDS. Using standard 
laboratory values for cytopenias [Hb <13g/dL (males), <12g/dL (females), ANC 
<1.8x109/L, platelets <150x109/L], the data demonstrated that only 1.8% patients 
evaluated in that study of 7012 MDS subjects would lack a cytopenia (1.3% 
patients when non-proliferative CMML patients were excluded). Of note, and 
relevant predominantly for patients with low marrow blast counts in the IWG-PM 
cohort, the patient's blood counts also needed to demonstrate ≥2 months of 
stable disease as a potential means of excluding other causes for the cytopenias.  
 Regarding our main point, it is of relevance that the MDS database 
(n=816) used to generate the IPSS (11, Table 1) similarly demonstrated that 19% 
of these patients lacked a cytopenia if defined by the prognostic level cutpoints 
used by the WHO and also incorrectly would not have been considered to have 
MDS. Similar findings were found in an independent study using these cytopenic 
cutpoints (13). Prior investigations have demonstrated ethnic-, age- and altitude-
related differences in normal hemoglobin levels (14, 15), ethnic-, age- and sex-
related differences in platelet levels (16,17), and ethnic- and sex-related 
differences in platelet and white counts (18). Thus, being cognizant of these 
conditional blood count variations, we recommend that standard hematologic 
values be used to define cytopenias in MDS and believe a modification of the 
WHO definition of cytopenias as one of the criteria (in addition to definitive 
morphologic and/or cytogenetic findings) to diagnose MDS would be valuable 
and most accurate. 
 
Table 1. Cytopenias in MDS 
 Cytopenias  
Marrow 
Blasts 
None 
n 
None 
% 
One 
n 
One 
% 
Two 
n 
Two 
% 
Three 
n 
Three 
% 
Total 
Less than normal* 
<5% 106 2.3 1946 43 1543 34 950 21 4545 
≥5% 19 0.8 421 17 927 38 1100 45 2467 
Total 125 1.8 2367 34 2470 35 2050 29 7012 
 
Less than normal, without CMML* 
<5% 73 1.7 1814 43 1395 33 912 22 4194 
≥5% 8 0.4 318 15 792 37 1047 48 2165 
Total 81 1.3 2132 34 2187 34 1959 31 6359 
 
WHO categorization** 
<5% 1040 23 1988 44 1064 23 453 10 4545 
≥5% 197 8 776 32 922 37 572 23 2467 
Total 1237 18 2764 39 1986 28 1025 15 7012 
*Standard values: Hb <13g/dL (males), <12g/dL (females), ANC <1.8x109/L, 
Platelets <150x109/L 
** IPSS values: Hb <10g/dL, ANC <1.8x109/L, Platelets <100x109/L 
Percent (%) values rounded off except for values <3%.  
Data obtained from reference 12. 
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